NCP Flanders
choose your programme
Horizon Europe

Horizon Europe is the main Research and Innovation Funding Programme of the European Commission.

Horizon 2020

Horizon 2020 is the previous Funding Programme. There are no longer calls, but projects can run until 2024.

Digital Europe

Digital Europe is a Funding Programme focused on bringing digital technology to businesses, citizens and administrations.

Other EU Funding

There are many other relevant EU funding programmes, managed by several agencies and directorates.

Event Calendar

Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020

Belgian Info Session: MSCA Doctoral Networks 2022 part 1

JUN
Thu
02
12:00 - 13:30

This was 1 year ago

Location

Online

Programmes

Slides and recordings are available on the event website 

UPDATE: Please note that the starting hour of this info session has been delayed to 12:00. The recording and slides will be made available after the webinar on the event website.

On the 2nd of June 2022 an info session on the Marie Sklodowska-Curie Actions (MSCA) Doctoral Networks 2022 call will take place. The event is organised by the National Contact Points (NCPs) for MSCA in Belgium (NCP Federal BENCP-FNRSNCP Flanders) to inform potential applicants and institutions from both the academic and non-academic sector.

The MSCA DN 2022 call will open on 12 May 2022 with a deadline on 15 November 2022. Doctoral Networks are consortia of at least 3 different entities (e.g. universities, research institutions and research infrastructures, businesses including SMEs, and other socio-economic actors) in different EU Member States and Horizon Europe Associated Countries, from various research and innovation areas (bottom-up approach). Supported researchers are doctoral candidates of any nationality. The Doctoral Networks can last for up to four years, and can cover all areas of research. Each fellowship is between 3 and 36 months. During this information session the objectives of DNs, call modalities and hands-on information on the application submission and evaluation process will be provided.

This is the first webinar about MSCA DN 2022 call. Please note that another one with testimonies from a coordinator of a successful proposal in MSCA DN 2021 call and from an expert evaluator will follow on 25 May. More information on the second session can be found on the event website.

The info session will take place online. It is free and open to any researcher in any career stage wishing to apply with a Belgian institution or any staff member of a Belgian institution (both from the academic and non-academic sector). Registration is mandatory and open until 1 June 2022. You have the possibility to write any question you might have at this stage in the registration form. Please take this opportunity, as all the questions raised beforehand will be addressed in the relevant presentations. 

myOVERVIEW
- sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon 2020 & Horizon Europe.

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.